A potential precision medicine approach for treating vision loss
Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide.
The study was published in Scientific Reports, and marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient’s tissue.
“Our vision is to develop a personalized approach to treating eye disease,” says Stephen Tsang, MD, PhD, the László Z. Bitó Associate Professor of Ophthalmology and associate professor of Pathology & Cell Biology at CUMC, ophthalmologist at NewYork-Presbyterian/Columbia, and one of the study’s senior authors. “We still have some way to go, but we believe that the first therapeutic use of CRISPR will be to treat an eye disease. Here we have demonstrated that the initial steps are feasible.”
In the study, the researchers created stem cells from a sample of skin that was taken from a patient with retinitis pigmentosa. As the patient-derived stem cells still harbored the disease-causing mutation, the teams used CRISPR to repair the defective gene. The stem cells can potentially be transformed into healthy retinal cells and transplanted back into the same patient to treat vision loss.
“The X-linked form of retinitis pigmentosa is an ideal candidate for a precision medicine approach because a common mutation accounts for 90% cases,” Tsang explains. Using CRISPR —which is easily adaptable to diverse sequences of DNA, and allows for fast and accurate editing —scientists can take a patient’s own cells and make pinpoint repairs specific to that individual’s genome.
Because the corrections are made in cells derived from the patient’s own tissue, doctors can re-transplant the cells with fewer fears of rejection by the immune system. Previous clinical trials have shown that generating retinal cells from embryonic stem cells and using them for transplantation is a safe and potentially effective procedure.
In this paper, the researchers targeted one of the most common variants of retinitis pigmentosa, which is caused by a single mistake in a gene called RGPR. The composition of RGPR—which contains many repeats and tight-binding nucleotide pairs—make it a difficult gene to edit. The researchers say that preliminary success with RGPR is therefore promising for treating other forms of the condition caused by mutations in other genes.
The current treatment for retinitis pigmentosa recommended by the National Institutes of Health—consuming high doses of vitamin A—slows down vision loss but does not cure the disease.
Other types of gene therapies for are currently undergoing clinical trials. Unlike CRISPR-based methods, these therapies introduce stretches of DNA that supplement some of the activity of the defective gene, but do not directly correct the original mutation. Follow-up studies have shown that any gains in vision from these gene supplementation therapies wane over time.
A CRISPR-driven precision medicine approach to treating retinitis pigmentosa may improve upon current therapies and restore a patient’s vision because CRISPR, with its pinpoint accuracy, can correct the fundamental genetic defect responsible for the disease. However, CRISPR technology has not yet been approved for use in humans.
The Latest on: Retinitis pigmentosa
via Google News
The Latest on: Retinitis pigmentosa
- AGTC Announces Two Key Leadership Team Appointmentson October 14, 2021 at 2:06 pm
We are excited to welcome Dr. Susan Schneider and Ms. Sarah DiSalvatore to AGTC during a pivotal time in our company’s history as we advance our X-Linked Retinitis Pigmentosa program into late-stage ...
- FDA Grants Fast Track Designation for GS030 in the Treatment of Retinitis Pigmentosaon October 13, 2021 at 9:27 am
Officials with the FDA have granted Fast Track designation to GS030 (GenSight Biologics) for the treatment of retinitis pigmentosa (RP). According to GenSight, GS030 combines AAV2 -based gene therapy ...
- US FDA grants fast tract designation to GenSight Biologics’ optogenetic therapy GS030 to treat Retinitis Pigmentosaon October 13, 2021 at 2:30 am
US FDA grants fast tract designation to GenSight Biologics’ optogenetic therapy GS030 to treat Retinitis Pigmentosa: Paris, France Wednesday, October 13, 2021, 15:00 Hrs [IST] G ...
- GenSight Gets Fast Track Designation For Optogenetic Therapy GS030 To Treat Retinitis Pigmentosaon October 12, 2021 at 6:25 am
The Fast Track designation granted by the FDA to GS030 highlights the significant unmet need for a safe and effective treatment of all forms of retinitis pigmentosa, the company said in a statement.
- AGTC to Present at Upcoming Cell & Gene Management Meeting on the Mesaon October 12, 2021 at 5:43 am
About AGTC AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a ...
- 4D Molecular presents Interim results from 4D-125 phase 1/2 trial in patients with advanced X-linked retinitis pigmentosa at ASRS meetingon October 12, 2021 at 2:00 am
D Molecular presents Interim results from 4D-125 phase 1/2 trial in patients with advanced X-linked retinitis pigmentosa at ASRS meeting: Emeryville, California Tuesday, October ...
- GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosaon October 11, 2021 at 10:30 pm
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...
- ASRS 2021: Single Gene Therapy Injection for Retinal Degenerative Diseaseon October 11, 2021 at 3:33 am
Findings from a Phase 1/2a clinical trial of its Multi-Characteristic Opsin (MCO) gene therapy for people blinded by retinitis pigmentosa (RP) were highlighted in two presentations during the 2021 ...
- How Running Has Helped Newton Nguyen Navigate Life as a Blind Manon October 8, 2021 at 3:02 pm
The day when the Ally Bank commercial ‘We Are All Better Off With An Ally’ first aired during the Tokyo Olympics, Newton Nguyen’s phone blew up with texts and calls. “Hey, I saw you in that Ally ...
- ReNeuron Approved to Restart Study on Retinitis Pigmentosa Therapyon October 1, 2021 at 12:25 am
By Jaime Llinares Taboada ReNeuron Group PLC said Friday that it has received approvals in all geographies to restart its study for the treatment of ...
via Bing News